West Point Pharmaceuticals stated in the Investor Relations Activity Record Form that the company has obtained a patent certificate for the invention of relaxanthin issued by the Japan Patent Office. The patent relates to the new use of roxianthin in the preparation of drugs to treat thyroid nodules. According to the company, the patent helps to enrich the intellectual property reserves of the product pipeline and provides legal protection for subsequent related drug research and development, registration and potential commercial application.

Zhitongcaijing · 2d ago
West Point Pharmaceuticals stated in the Investor Relations Activity Record Form that the company has obtained a patent certificate for the invention of relaxanthin issued by the Japan Patent Office. The patent relates to the new use of roxianthin in the preparation of drugs to treat thyroid nodules. According to the company, the patent helps to enrich the intellectual property reserves of the product pipeline and provides legal protection for subsequent related drug research and development, registration and potential commercial application.